These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36533308)

  • 1. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
    Banerjee S; Baidya SK; Adhikari N; Jha T
    SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure-activity relationship (q-RASAR) and pharmacophore modeling.
    Khatun S; Dasgupta I; Islam R; Amin SA; Jha T; Dhaked DK; Gayen S
    Mol Divers; 2024 Aug; 28(4):2197-2215. PubMed ID: 38871969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
    Banerjee S; Adhikari N; Amin SA; Jha T
    J Biomol Struct Dyn; 2020 Mar; 38(5):1551-1564. PubMed ID: 31074329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Importance of Structural Water in HDAC8 for Correct Binding Pose Applied for Drug Design of Anticancer Molecules.
    Morales-Herrejón G; Mendoza-Figueroa HL; Martínez-Archundía M; Correa-Basurto J
    Anticancer Agents Med Chem; 2024; 24(15):1109-1125. PubMed ID: 38835122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
    Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
    Banerjee S; Adhikari N; Amin SA; Jha T
    Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
    Kashyap K; Kakkar R
    Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
    Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
    Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
    Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
    Thangapandian S; John S; Lee Y; Kim S; Lee KW
    Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
    Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
    Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
    Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
    Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
    Adhikari N; Amin SA; Jha T
    Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
    Hassan MM; Israelian J; Nawar N; Ganda G; Manaswiyoungkul P; Raouf YS; Armstrong D; Sedighi A; Olaoye OO; Erdogan F; Cabral AD; Angeles F; Altintas R; de Araujo ED; Gunning PT
    J Med Chem; 2020 Aug; 63(15):8634-8648. PubMed ID: 32672458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
    Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
    Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.